BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen und mRNA-HerstellungInsgesamt wurden etwa 86,75 Prozent der CureVac-Aktien angedient; BioNTech geht davon aus, dass der obligatorische Erwerb der verbleibenden CureVac-Aktien im Januar 2026 im Rahmen der zuvor angekündigten Nach-Angebots-...
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganizationCureVac will continue to operate unde...
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespec...
Erste Ergebnisse aus BioNTechs und BMS’ globaler Phase-2-Studie mit bispezifischem PD-L1xVEGF-A-Antikörperkandidat Pumitamig zeigten ermutigende Anti-Tumor-Aktivität bei fortgeschrittenem dreifach negativem Brustkrebs Zwischenergebnisse der globalen klinischen Phase-2-Studie bei lokal fortgeschrittenem/metastasiertem dreifach negativem Brustkrebs (triple-negative breast cancer, „TNBC“) zeigten eine ermutigende Anti-Tumor-Aktivität für Pumitamig (BNT327/BMS986545) in Kombination mit Chemotherapie bei Patientinnen und Patienten in der Erst- oder ZweitlinienbehandlungPumitamig in Kombination m...
BioNTechs und OncoC4s selektiver Treg-Modulatorkandidat Gotistobart erzielte klinisch relevanten Gesamtüberlebensvorteil bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge Der selektive Treg-Modulatorkandidat Gotistobart (BNT316/ONC-392) zeigte eine Verringerung des Sterberisikos um mehr als die Hälfte im Vergleich zur Standard-Chemotherapie sowie ein kontrollierbares Sicherheitsprofil im ersten von zwei Abschnitten der globalen, klinischen Phase-3-Studie PRESERVE-003 bei Patientinnen und Patienten mit Plattenepithelkarzinom der Lunge (squamous non-small c...
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care chemotherapy and a manageable safety profile in the first of two stages of the global Phase 3 trial PRESERVE-003 in patients with squamous non-small cell lung cancer (“sqNSCLC”) who have progressed on prior immunotherapy plus chemotherapyMedian OS with gotistobart ha...
MEETING OF THE SUPERVISORY BOARD OF UNIBAIL-RODAMCO-WESTFIELD N.V. Amsterdam, December 4, 2025 Press Release MEETING OF THE SUPERVISORY BOARD OF UNIBAIL-RODAMCO-WESTFIELD N.V. On December 4, 2025, the Supervisory Board of Unibail-Rodamco-Westfield N.V. (“URW NV”) met and took note of the resignation of the Chairman and Member of the Supervisory Board, Mr. Jean-Marie Tritant, who will resign as of December 31, 2025. URW NV announces that Mr. Vicent Rouget is designated as temporary replacement as Chairman and member of the Supervisory Board effective as of January 1, 2026. Mr. Rouget wi...
URW SE - Information on total number of voting rights and shares in the share capital as at November 30, 2025 Paris, December 3rd, 2025 Information on total number of voting rights and shares in the share capital as of November 30th, 2025 (Article L.233-8-II of the French Commercial Code and Article 223-16 of the General Regulation of the AMF) DateTotal number of shares in the capitalTotal number of voting rights30/11/2025143,334,100143,334,100 UNIBAIL-RODAMCO-WESTFIELD SEA European Company with Management Board and Supervisory BoardShare capital: €716,670,500Registered office: 7 place du...
URW SE - Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2025 Paris, le 3 décembre 2025 Informations relatives au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’AMF) DateNombre total d’actions composant le capitalNombre total de droits de vote30/11/2025143 334 100143 334 100 UNIBAIL-RODAMCO-WESTFIELD SESociété Européenne à Directoire et Conseil de surveillanceau capital de 716 670 500 euros Siè...
URW appoints Kathleen Verelst as Chief Investment Officer Paris, December 3, 2025 Press release URW appoints Kathleen Verelst as Chief Investment Officer Unibail-Rodamco-Westfield (“URW”, “the Group”) announces that at its meeting today the Supervisory Board, upon the recommendation of its Governance, Nomination and Remuneration Committee (“GNRC”), decided the appointment of Kathleen Verelst as Chief Investment Officer (CIO) and a member of its Management Board, effective January 1, 2026. Kathleen has more than 30 years of global real estate experience, working for a leading internati...
BioNTech erfüllt Mindestannahmebedingungen im Rahmen des Umtauschangebots für CureVac-Aktien Mindestannahmebedingung für das Angebot wurde erfüllt; es wurden vor Ablauf der ursprünglichen Angebotsfrist insgesamt 184.071.410 CureVac-Aktien angedient, was etwa 81,74 % der ausgegebenen und im Umlauf befindlichen CureVac-Aktien entsprichtDie Nachangebotsfrist hat begonnen und endet am Donnerstag, den 18. Dezember 2025, um 6:01 Uhr MEZ (0:01 Uhr EST) MAINZ, Deutschland, 3. Dezember 2025 – h SE (Nasdaq: BNTX, „BioNTech“) gab heute bekannt, dass 184.071.410 Aktien der CureVac N.V. (Nasdaq: CVA...
BioNTech Achieves Minimum Condition in CureVac Exchange Offer The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025 MAINZ, Germany, December 3, 2025 – (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% o...
A director at RWE AG bought 700 shares at 43.300EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...
BioNTech informiert über Fortschritte im Rahmen des Umtauschangebots für CureVac-Aktien und weist auf Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ hin Ablauf des Angebots am 3. Dezember 2025 um 15 Uhr MEZ (9:00 Uhr EST); CureVac-Aktionärinnen und -Aktionären wird empfohlen, ihre Aktien aufgrund operativer Fristen bis spätestens 3. Dezember 2025, 0:00 Uhr MEZ (2. Dezember 2025 um 18:00 Uhr EST) anzudienenErmittlung des Umtauschverhältnisses von 0,05363 einer BioNTech American Depositary Share („ADS“) je CureVac-Aktie auf Grundlage des volumengewichteten Durchschnittskurses der BioN...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.